<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498524</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001258</org_study_id>
    <nct_id>NCT00498524</nct_id>
  </id_info>
  <brief_title>Risk of Life-threatening Heart Rhythm Disturbances in Siblings</brief_title>
  <acronym>SIBFIB</acronym>
  <official_title>The Sibling Concordance for Implantable Cardioverter-defibrillator Therapies in Ischemic Cardiomyopathy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if heredity influences the risk of life-threatening&#xD;
      heart rhythms (ventricular tachycardia and ventricular fibrillation) after heart attack&#xD;
      (myocardial infarction).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Greater than 400,000 persons die suddenly each year in the US. The implantable&#xD;
      cardioverter-defibrillator (ICD) has revolutionized the primary prevention of sudden cardiac&#xD;
      death (SCD) following myocardial infarction (MI), however, risk stratification remains&#xD;
      limited and rests solely on the identification of left ventricular dysfunction. The goal of&#xD;
      this study is to determine if genetic factors influence the risk of ventricular arrhythmia&#xD;
      remotely after myocardial infarction.&#xD;
&#xD;
      In order to determine if ventricular tachycardia or ventricular fibrillation remotely after&#xD;
      MI is a heritable trait, we will conduct a family based case-control sibling study of&#xD;
      patients who have received an ICD for ischemic cardiomyopathy. As a first step, we will&#xD;
      utilize the GENECARD registry, an existing family linkage study of premature cardiovascular&#xD;
      disease, to determine the prevalence of sibling concordance for ICD implantation following&#xD;
      MI. Probands and siblings in the GENECARD study will be surveyed regarding their ICD history.&#xD;
      The sibling recurrence risk ratio for ICD implantation following MI and subsequent ICD&#xD;
      therapies will be used to estimate the sample size required to validate heritability, in a&#xD;
      larger patient population. In the validation phase of this protocol, we will use a (1) single&#xD;
      healthcare system database (Duke Cardiovascular Databank) and a (2) regional population-based&#xD;
      registry, in order to determine concordance for ICD therapies. Patients who agree to&#xD;
      participate and provide informed consent will be surveyed regarding their personal ICD&#xD;
      history and that of their siblings. The prevalence of ICD therapies will be ascertained in&#xD;
      the probands, siblings, and the overall cohort. Sibling concordance for ICD implantation and&#xD;
      sibling concordance for subsequent appropriate ICD therapies will be used to determine the&#xD;
      sibling recurrence risk ratio for appropriate ICD therapies remotely after MI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ICD Discharge</measure>
    <time_frame>Long-term follow up</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2047</enrollment>
  <condition>Defibrillators, Implantable</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Tachycardias, Ventricular</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Sib who has received an ICD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Sib who has not received an ICD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <description>Received an ICD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <description>Have not received an ICD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Post-MI population with LV dysfunction and an implantable cardioverter-defibrillator.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients must be alive&#xD;
&#xD;
          -  have a history of coronary artery disease / myocardial infarction&#xD;
&#xD;
          -  left ventricular ejection fraction â‰¤ 35%&#xD;
&#xD;
          -  received an implantable cardioverter- defibrillator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  nonischemic cardiomyopathy&#xD;
&#xD;
          -  Pre-identified hereditary arrhythmia syndrome (e.g. long QT syndrome, Brugada&#xD;
             syndrome, etc)&#xD;
&#xD;
          -  left ventricular ejection fraction &gt;35%&#xD;
&#xD;
          -  no implantable cardioverter-defibrillator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick M Hranitzky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan P Piccini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center, Division of Cardiology - Electrophysiology Section</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jonathan P Piccini</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>implantable cardioverter-defibrillator</keyword>
  <keyword>ischemic cardiomyopathy</keyword>
  <keyword>ventricular arrhythmias</keyword>
  <keyword>sibling concordance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

